Argos Therapeutics, Inc. is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases and transplantation rejection. The Company is pioneering the development of individualized immunotherapy, using its combined mRNA and dendritic cell technology to deliver specifically targeted treatments, one patient at a time. Using material from both disease and blood samples collected from each patient, its Arcelis-based immunotherapies arm the patient’s dendritic cells to trigger a targeted patient-specific immune response.

Type
Public
HQ
Durham, US
Founded
1997
Size (employees)
122 (est)-10%
Argos Therapeutics was founded in 1997 and is headquartered in Durham, US
Report incorrect company information

Key People/Management at Argos Therapeutics

Richard Katz

Richard Katz

Chief Financial Officer
Hubert Birner

Hubert Birner

Chairman of the Board
Lori Harrelson

Lori Harrelson

Vice President, Finance
Charles Nicolette

Charles Nicolette

Chief Scientific Officer and VP, Research and Development

Argos Therapeutics Office Locations

Argos Therapeutics has an office in Durham
Durham, US (HQ)
4233 Technology Dr
Show all (1)
Report incorrect company information

Argos Therapeutics Financials and Metrics

Argos Therapeutics Financials

Argos Therapeutics's revenue was reported to be $945.47 k in FY, 2016 which is a 82.4% increase from the previous period.
USD

Revenue (Q2, 2017)

69.7 k

Net income (Q2, 2017)

(8.5 m)

EBIT (Q2, 2017)

(8.1 m)

Market capitalization (5-Feb-2018)

4.2 m
Argos Therapeutics's current market capitalization is $4.2 m.
Annual
USDFY, 2014FY, 2015FY, 2016

Revenue

2 m518.3 k945.5 k

Revenue growth, %

(74%)82%

General and administrative expense

8.6 m11 m14.2 m

R&D expense

45.5 m62.1 m38.3 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

798.8 k473.2 k398.6 k178.8 k107.4 k158.3 k146.4 k488.6 k146.8 k105.3 k69.7 k

General and administrative expense

1.9 m1.9 m2.3 m2.4 m2.9 m2.7 m3 m3.4 m3 m4 m2.7 m

R&D expense

8.5 m10.6 m13 m14.8 m16.1 m17.2 m9.5 m9.2 m9.3 m7.9 m5.1 m

Operating expense total

10.4 m12.4 m15.3 m17.1 m19 m19.9 m12.5 m12.6 m12.4 m44.1 m8.1 m
Annual
USDFY, 2014FY, 2015FY, 2016

Cash

37.2 m6.2 m53 m

Accounts Receivable

129 k73.8 k136.1 k

Current Assets

57.5 m8.8 m55.5 m

PP&E

5.5 m22.3 m41 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

51.8 m44.3 m50.3 m29 m23 m20 m13.8 m34.8 m69.3 m

Accounts Receivable

569 k265.5 k163.2 k163.7 k57 k130.8 k91.4 k461.1 k119.3 k137.2 k42.2 k

Current Assets

84.8 m72.9 m70.9 m40.4 m33 m24.9 m15.5 m37.3 m71.3 m25.5 m21.9 m

PP&E

1.7 m1.8 m4.5 m11.2 m15.5 m19 m27.3 m29.1 m37.5 m4.3 m4.1 m
Annual
USDFY, 2014FY, 2015FY, 2016

Net Income

(53.3 m)(74.8 m)(53 m)

Depreciation and Amortization

566.1 k680.4 k952.3 k

Accounts Payable

543.4 k(137 k)1.2 m

Cash From Operating Activities

3.9 m(31.1 m)(40.7 m)
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(10 m)(12 m)(15.1 m)(17.5 m)(19.6 m)(20.1 m)(12.8 m)(12.6 m)(12.2 m)(24.1 m)

Accounts Payable

2.2 m3.1 m3.6 m4.7 m3.1 m6.2 m5.1 m3.6 m3.4 m
USDY, 2017

Financial Leverage

-1.3 x
Show all financial metrics
Report incorrect company information